What bispecific antibody therapies are being tested in multiple myeloma clinical trials?
Current research is exploring bispecific antibodies that target various molecules on myeloma cells, including:
B-cell maturation antigen (BCMA): This is a protein highly expressed on the surface of myeloma cells, making it an attractive target for bispecific antibodies.
G protein-coupled receptor class C group 5 member D (GPRC5D): This is another protein found on myeloma cells being investigated as a target for bispecific antibodies.
Fc receptor-homolog 5 (FCRh5): FcRH5 is notably overexpressed inmultiple myeloma cells and is an upcoming target being tested for bispecific antibodies.
To view the bispecific antibody therapies that are approved, visit the section: FDA-Approved Bispecific Antibodes. Other antibodies listed above are in clinical trial staging and are not currently approved for treatment.
